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1. Introduction 
The prostaglandins are a group ofhormones, derived 
from essential fatty acids, which exhibit a broad 
spectrum of pharmacological effects as diverse as the 
inhibition of platelet aggregation and the regulation 
of intestinal fluid secretion [ 11. Prostaglandins, and 
likewise, catecholamines and glucagon, act on the 
cell by elevating the intracellular level of CAMP [2,3]. 
The precise mechanism by which CAMP formation is 
stimulated by hormone still remains to be elucidated, 
despite the great amount of work which has been 
carried out on this system in recent years [3]. Never- 
theless, it is clear that two distinct events occur; 
binding of hormone to its receptor and the subsequent 
stimulation of adenylate cyclase. 
Since the floating receptor hypothesis was first 
proposed [4], the non-identity of receptor and aden- 
ylate cyclase has been proved by a variety of tech- 
niques [5-91. Undoubtedly, it is the complexity of 
the system which has frustrated our understanding of 
it and this being the case, it would clearly be advan- 
tageous to examine each component separately, 
removed from its membraneous milieu, since the 
membrane itself can also influence the properties of 
integral components [lO,ll]. 
Here we report the solubilization of prostaglandin 




[5,6-3H]PGE1 (50 Ci/mmol) and [14C]protein 
hydrolysate (57 mCi/matom carbon) were purchased 
Elsevier/North-Holland Biomedical Press 
from the Radiochemical Centre, Amersham; guanylyl- 
imido-diphosphate (Gpp(NH)p), Lubrol PX, neur- 
aminidase (type V), PGEl and phospholipase C 
(type X) from Sigma; trypsin from Difco. All other 
chemicals were of analytical grade. The ultrafiltration 
equipment is the product of the Amicon Corporation. 
2.2. Preparation of homogenate 
P388 mouse lymphatic leukaemia cells were grown 
and homogenised as in [ 121, except that 0.05 /&i/ml 
[ “C]protein hydrolysate was included in the growth 
medium, 4 days before harvesting the cells, as a mem- 
brane marker. The homogenate was stored under 
liquid nitrogen, aliquots being taken when required 
and resuspended in buffer (10 mM Tri-HCI, pH 7.6 at 
2O”C, 0.15 M NaCl) following centrifugation at 
40 000 X g for 20 min (4’C). 
2.3. Solubilization of the PGEl-binding components 
Homogenate (1 mg protein by the Lowry method 
[ 131) was incubated in 0.27 ml buffer for 30 min at 
30°C together with 2 mM MgC12, 0.15 PM [5 ,6-3H]PGE, 
and any other component, as described below. All 
subsequent steps were carried out at 4°C. 
The suspension was eluted through a column 
(8.6 X 1.2 cm) of Sephadex G-50 Fine with buffer, 
the void volume was collected and centrifuged at 
40 000 X g for 20 min. The pellet was resuspended 
in 0.6 ml buffer, to which 0.3 ml 0.15% (w/v) 
Lubrol PX in buffer was added subsequently. This 
suspension was incubated for 30 min, during which 
time it was periodically agitated on a vortex mixer, 
then centrifuged at 60 000 X g for 20 min. 
The supernatant was concentrated by ultrafiltra-’ 
tion in a Centriflo CF-25 cone for 15 min at 800 X g. 
The concentrate, 200 ~1, was applied to a column 
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(18.2 X 0.8 cm) of Sepharose CL6B, pre-equilibrated 
with buffer containing 0.05% (w/v) Lubrol PX and 
eluted at a 9 ml/h flow rate. 200 ~1 fractions were 
collected directly into plastic mini scintillation vials 
to which 2.4 ml Triton-toluene fluor containing 
PPO and POPOP was added. 
2.4. Liquid scintillation counting 
Samples were counted in a Packard model 3385 
liquid scintillation spectrometer for 20 min each, 
using the preset channels for 3H and ry dual label- 
ling. Counting efficiencies were 2 1% and 57%, whilst 
backgrounds were 7 cpm and 6 cpm for 3H and r4C, 
respectively; 47% of the r4C cpm spilt over into the 
3H channel. Results were converted to dpm by an 
off-line computer. 
3. Results 
Prostaglandin El binding was assayed by incubat- 
ing P388 homogenate at 30°C with labelled PGEr. 
Free hormone was removed by Sephadex chromatog 
raphy and the homogenate was then treated with 0.05% 
Lubrol PX, a concentration found to be optimal for 
the solubilization of active adenylate cyclase from 
P388 (unpublished data). The solubilized material 
was concentrated, then fractionated on Sepharose 
CL6B with complete recovery of the applied radio- 
activity. This method is reproducible and a typical 
example is given in fig. 1. Specific binding is repre- 
sented by the difference (not shown) of the total 
and non-specific binding. 
Non-specific binding was only 15% of the total and 
dPm 
300' 
elution volume (cmw3) 
Fig.1. Fractionation of PGE,binding components. [ 5,6-“H]PGE, was bound to P388 homogenate, which was then solubihzed 
and fractionated as described in section 2. Total binding (e-0) was assayed for in the absence of unlabelled PGE,, whilst non- 
specific binding (O-O) included 37 MM unlabelled PGE, in the incubation mixture. Fractionation of the ‘*C marker label is also 
shown (A-A). Molecular weight markers were: (a) thyroglobulin, 67 X 104; (b) aldolase, 14 x 10’; (c) haemoglobin, 6 x 10’; (d) 
cytochrome c, 12 X 10’. 
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was distinguishable from specific binding on account 
of their different elution volumes. This level of non- 
specific binding was made possible by the use of 
Sephadex chromatography, which gave a 12-fold 
enhancement i  the ratio of specific/non-specific 
binding. Reaction of the non-specific binding was 
thought o be due to both removal of free [5,6-‘H]PGEr 
and to the partial purification of plasma membrane, 
since much of the homogenate was unable to pass 
through the Sephadex column. 
The 14C-marker label (fig. 1) was presumably 
incorporated into lipid, as it co-migrated with the 
non-specific PGEr-binding component. 
Dissociation of bound [5,6-‘H]PGEr, during and 
after solubilization, accounts for the label eluting in 
the total volume fraction. Prior to solubilization, no 
free label could be detected. 14C was never detected 
in the total volume fraction. 
Treatment of the homogenate with trypsin, phos- 
pholipase C or neuraminidase, during the incubation 
with [5,6-3H]PGE1 resulted in a reduction in the 
molecular weight of the specific PGEi-binding com- 
ponent. Solubilization and fractionation of the mem- 
brane with 0.45% Lubrol reduced the molecular 
weights of both the specific and non-specific PGEr- 
binding components (data not shown). The increased 
Lubrol concentration did not significantly improve 
the yield of bound PGEr, apparently because the rate 
of dissociation was also enhanced [8]. 
The presence of 0.1 mM Gpp(NI-I)p in the PGEr- 
binding incubation caused the complete loss of specific 
PGEr binding, resulting in an elution profile identical 
to that for non-specific PGEr binding (fig.1). 
4. Discussion 
Evidence that the observed specific [5,6-‘H]PGEi 
binding is indeed binding to the bona fide receptor, 
is that the K, for binding and the K, for adenylate 
cyclase activation by PGEi, in particulate preparations 
of P388, are of the same order, i.e., 40 nm [12,14]. 
The receptor density is 0.4 pmol/mg membrane pro- 
tein [ 141, which corresponds to 2000 receptors/cell. 
Moreover, we have shown here that specific binding 
is completely abolished in the presence of 0.1 mM 
Gpp(NH)p. GTP and its analogues are known to 
reduce the receptor affinity for agonists, whilst 
having no effect on antagonist binding [ 15-181. 
The prostaglandins, being derived from fatty acids, 
are an enigmatic group of hormones. It has been 
suggested that the hormone receptor site is consti- 
tuted by the receptor/membrane lipid interface 
[ 19,201 and if this is indeed the case, one could 
envisage the membrane lipids playing a predominant 
role in the PGEr receptor. This report, however, 
shows that it is possible to solubilize specific PGEr- 
binding components in the same manner as the 
/3-adrenergic receptor [6,8,21], the gonadotropin 
receptor [22] and the glucagon receptor [23]. Fur- 
thermore, the apparent molecular weight of the 
specific PGEr-binding components, although some- 
what heterogeneous, lies within the same range as 
that of other solubilized receptors [7,21,22], namely 
2-5 X 10’. Perhaps this is not surprising, when one 
considers that these receptors have to satisfy pre- 
sumably stringent conditions in order to couple 
satisfactorily with adenylate cyclase. 
The effect of trypsin, phospholipase C,neur- 
aminidase and 0.45% Lubrol on the reduction of 
the PGEr-binding components’ molecular weight 
range is probably due to the breakdown of an aggre- 
gate of PGEr receptor, membrane lipid and protein; 
resistance of specific PGEr binding to trypsin action 
suggests hat the receptor is buried within the plasma 
membrane, inaccessible toproteolytic attack. 
In conclusion, we have shown that specific .PGEr- 
binding components, assayed with an agonist, can be 
solubilized from cultured mammalian cells. Within the 
limits of our current knowledge, these components are 
very similar to those other receptors which interact 
with adenylate cyclase. 
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